The sensitizing/activating mutations (exon 19 deletions and point mutation L858R located in exon 21) are the most common, and NSCLC patients bearing these mutations usually respond well to EGFR TKI therapy [7,8]. Here, EGFR is linked to non-small cell lung carcinoma.